secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2022-10-24T23:59:59+00:00
Accession:  0001193125-22-267186
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics launches RT-111 oral ustekinumab biosimilar; RT-102 data due Q4 2022; RT-109 halted
--------------------------------------------------------------------------------

- Preclinical development started for RT-111, an oral ustekinumab biosimilar for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
- RT-102 Phase 1 Part 2 (repeat-dose) topline data expected in Q4 2022; Phase 2 planned for H2 2023.
- In vivo studies with fully-autonomous RaniPill HC (high-capacity capsule) anticipated in Q4 2022.
- Active development of RT-109 (human growth hormone) discontinued; Rani open to partnering opportunities.
- Three additional Phase 1 studies targeted for 2023: RT-105 (adalimumab biosimilar), RT-110 (PTH for hypo-parathyroidism), and RT-111.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000119312522267186/0001193125-22-267186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000119312522267186/d308091d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-267186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer